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Rapport de synthèse 
Objectifs : évaluer la survie intra-hospitalière des patients présentant un infarctus du myocarde avec 
sus-décalage du segment ST admis dans les hôpitaux suisses entre 2000 et 2007, et identifier les 
paramètres prédictifs de mortalité intra-hospitalière et d'événements cardio-vasculaires majeurs 
{infarctus, reinfarctus, attaque cérébrale). 
Méthode: utilisation des données du registre national suisse AMIS Plus {Acute Myocardial lnfarction 
and Unstable Angina in Switzerland). Tous les patients admis pour un infarctus du myocarde avec 
sus-décalage du segment ST ou bloc de branche gauche nouveau dans un hôpital suisse participant 
au registre entre janvier 2000 et décembre 2007 ont été inclus. 
Résultats : nous avons étudié 12 026 patients présentant un infarctus du myocarde avec sus-
décalage du segment ST ou bloc de branche gauche nouveau admis dans 64 hôpitaux suisses 
différents. L'âge moyen est de 64 ± 13 ans et 73% des patients inclus sont des hommes. L'incidence 
de mortalité intra-hospitalière est de 7.6% en 2000 et de 6% en 2007. Le taux de réinfarctus diminue 
de 3.7% en 2000 à 0.9% en 2007. L'utilisation de médicaments thrombolytiques chute de 40.2% à 2% 
entre 2000 et 2007. Les paramètres prédictifs cliniques de mortalité sont : un âge> 65 ans, une classe 
Killips Ill ou IV, un diabète et un infarctus du myocarde avec onde Q {au moment de la présentation). 
Les patients traités par revascularisation coronarienne percutanée ont un taux inférieur de mortalité 
et de réinfarctus {3.9% versus 11.2% et 1.1% versus 3.1%, respectivement, p<0.001) sur la période de 
temps étudiée. Le nombre de patients traités par revascularisation coronarienne percutanée 
augmente de 43% en 2000 à 85% en 2007. Les patients admis dans les hôpitaux bénéficiant d'une 
salle de cathétérisme cardiaque ont un taux de mortalité plus bas que les patients hopitalisés dans 
les centres sans salle de cathétérisme cardiaque. Mais les charactéristiques démographiques de ces 
deux populations sont très différentes. 
La mortalité intra-hospitalière ainsi que le taux de réinfarctus diminuent significativement au cours 
de la période étudiée, parallèlement à l'augmentation de l'utilisation de la revascularisation 
coronarienne percutanée. La revascularisation coronarienne percutanée est le paramètre prédictif 
de survie le plus important. 
Conclusion : la mortalité intra-hospitalière et le taux de réinfarctus du myocarde ont diminué de 
manière significative chez les patients souffrant d'un infarctus du myocarde avec sus-décalage du 
segment ST au cours de ces sept dernières années, parallèlement à l'augmentation significative de la 
revascularisation coronarienne percutanée en plus de la thérapie médicamenteuse. La survie n'est 
pas liée au lieu d'hospitalisation mais à l'accès à une revascularisation coronarienne percutanée. 
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Summary 
Objectives: To evaluate the in-hospital out-
come of STEMI (ST elevation myocardial infarc-
tion) patients admitted to Swiss hospitals between 
2000 and December 2007, and to identify the pre-
dictors of in-hospital mortality and major cardiac 
events. 
Methods: Data from the Swiss national reg-
istry AMIS Plus (Acute Myocardial Infarction and 
Unstable Angina in Switzerland) were used. AU 
patients admitted betweenJanuary 2000 and De-
cember 2007 with STEMI or a new LBBB (left 
bundle branch block) were included in the reg-
istry. 
ReSZtlt: We studied 12 026 STEMI patients 
admitted to 68 hospitals. The mean age was 64 
± 13 years and 73 % of the patients were male. In-
cidence of in-hospital death was 7 .6% in 2000 and 
6% in 2007. Reinfarction fell from 3.7% in 2000 
to 0.9% in 2007. Thrombolysis decreased from 
40.2% in 2000 to 2% in 2007. Clinical predictors 
of mortality were: age >65 years, Killips class III 
or rv, diabetes, Q wave myocardial infarction (at 
presentation). Patients undergoing percutaneous 
Introduction 
Reperfusion and prompt restoration of ante-
grade coronary blood flow results in myocardial 
salvage and improved left ventricular function and 
survival [1-3] of patients with acute myocardial in-
farction. Both thrombolytic therapy and percuta-
coronary intervention (PCI) had lower mortality 
and reinfarction rates (3. 9% versus 11.2 % and 
1.1 % versus 3.1 % respectively, p <0.001) over 
time, although their numbers increased from 
43 % in 2000 to 85% in 2007. Patients admitted to 
hospitals with PCI facilities had lower mortality 
than patients hospitalised in hospitals without it, 
but the demographic characteristics differ widely 
between the two groups. 
· Bath in-hospital mortality and reinfarction 
decreased significantly over the time, parallel to 
an increased number of PCI. PCI was also the 
strongest predictor of survival. 
Conclusion: In-hospital mortality and reinfarc-
tion rate have decreased significantly in Swiss 
STEMI patients in the last seven years, parallel to 
a significant increase in the number of percuta-
neous coronary interventions in addition to med-
ical therapy. Outcome is not related to the site of 
admission but to PCI access. 
Key words: myocardial infarction; angioplasty, 
STEMI,PCI 
neous coronary intervention (PCI) are used to 
open the infarct-related artery [4-6]. Severa! ran-
domised trials favour PCI over thrombolysis [7-
16], especially in high risk patients [11, 17] due to 
a higher patency rate, less reocclusion, recurrent 
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ischaernia, reinfarction, and stroke [18-21]. 
Thrombolysis and medical management remain 
the first choice treatment in some hospitals with-
out PCI capabilities, because of strategic con-
straints. Previous studies have shown that on site 
PCI is a major determinant of patient manage-
ment. However, it is still an open question 
whether the outcome of patients admitted to hos-
pitals with or without PCI capability is the same 
Methods 
Data from the Swiss national registry on myocardial 
infarction AMIS Plus were used. 
The AMIS Plus Registry 
Since 1997 this Swiss prospective national registiy 
has collected data from patients admitted with a definitive 
diagnosis of acute coronary syndrome in Switzerland 
(AMIS Plus). It is a prospective data bank monitored by a 
Data Centre (Institute of Social and Preventive Medicine 
at the University of Zürich) providing blinded data of 
Swiss STEMI and non-STEMI patients. It is a complete 
cohort of Swiss patients. Data are collected by an inter-
net- and/or paper-based questionnaire of 140 questions, 
related to patient hist01y, clinical parameters, previous 
medical hist01y, laboratory parameters, in-hospital and 
discharge ti·eatment, hospitalisation outcome and desti-
nation at discharge. The questionnaire is completed by 
physicians and research nurses and has been described 
previously [22]. 
Patients are enrolled in the registry on the basis of 
final diagnosis, which must comply with one of the fol-
lowing three definitions: acute myocardial infarction 
(symptoms or ECG changes compatible with acute coro-
na1y syndrome, or bath, and cardiac enzymes (total crea-
tine kinase (CK) or CK-MB) at least twice the upper limit 
of normal range); acute coronaiy syndrome with mini-
mum necrosis (symptoms or ECG changes compatible 
with acute coronaiy syndrome, or bath, and cardiac en-
zymes (total CK or CK-MB) lower than twice the upper 
limit of normal range, and positive troponins); and unsta-
ble angina (symptoms or ECG changes compatible with 
acute coronary syndrome, or bath, and normal cardiac en-
zymes). Cases that are of unclear or non-cardiac cause are 
not included. 
For this article we analyzed only patients with 
STEMI. 
The project is led by a Steering Committee and was 
approved by the Supraregional Ethical Committee for 
Clinical Studies and the Swiss Board for Data Security. 
Results 
Baseline characteristics 
Patient demographics and characteristics are 
presented in table 1. A total of 12 026 patients 
(73 % male) with a mean age of 64 ± 13 years were 
treated for STEMI and included in the database. 
In-hospital mortalitywas 6.9%, reinfarction 1.9% 
or not, merely because the strategy and the infra-
structure are different. 
We evaluated the Swiss STEMI (ST elevation 
myocardial infarction) patients over time to de-
tect change in management (in line with the 
evolving guidelines) and possibly in their progno-
sis. We also evaluated the clinical predictors of 
in-hospital mortality, reinfarction and stroke. 
Study population 
BetweenJanuaiy 2000 and December 2007, patients 
with STEMI or new left bundle branch black (LBBB) 
were included in the registiy. These patients were filtered 
out of the AMIS Plus collective according to the dis-
charge diagnosis. American Heart Association/ American 
College of Cardiology (AHA/ACC) guidelines were fol-
lowed for patient management. Physicians were allowed 
to use thrombolysis and/or PCI in bath types of hospital 
when needed. Patients hospitalised in establishments 
without PCI facilities had to be transferred for PCI. 
Patient characteristics 
Demographic data, clinical variables, procedures, 
and events were collected at admission and during the 
hospital stay by physicians and dedicated nurses. 
Statistics 
Al! analyses were performed by the AMIS Plus Data 
Centi·e. Al! categorical measures are reported as counts 
with percentage and valid values. Pearsons chi-square 
were used for group comparisons. The chi-square tests 
were two-sided. Al! p values were two-sided and were con-
sidered significant if <0.05. A multivariate logistic mode! 
was used to determine in-hospital mortality predictors 
from the following set of variables: admission year; age; 
sex; systolic and diastolic blood pressures; heart rate; his-
tory of arterial hypertension; histmy of dyslipidaemia; 
hist01y of diabetes; current smoking status; cardiopul-
mona1yresuscitation before admission; defibrillation/car-
dioversion before admission; Killip class at hospital ad-
mission (class I as reference category); delay between 
symptom onset and admission to hospital >6 hours; Q 
waves on initial ECG; left bundle branch black on initial 
ECG; ST segment elevation on initial ECG; thromboly-
sis; prima1y PCI, cath-lab at hospital of admission. Sepa-
rate univariate logistical models were first fitted for each 
variable and then backwards elimination with a signifi-
cance level of 0.05 was performed. We represent in tables 
3 and 4 only the significant predictors of death and major 
adverse cardiac events (MACE). Missing data are given in 
the tables and are not included in the analysis. 
and stroke 1 % (table 2). The incidence of death, 
reinfarction and stroke declined significantly over 
time from 7.6% in 2000 to 6.5% (p = 0.004) 
in 2007 for mortality, and from 3.7% to 1 % 
(p <0.001) for reinfarction. The incidence of 
stroke decreased over time from 1.8% in 2000 to 
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Table 1 
Baseline 
characterist ics. 
Table 2 
Patients outcome. 
In-hospita li ty mortality 
Reinfarction 
Stroke 
Figure 1 
N 12 026 
Males 8828 (73%) 
Mean age 64 ± 13 years 
Killip I-II 11130 (93%) 
Killip III-IV 845 (7%) 
Q waves (at admission) 1971 (16.8%) 
Hypertension 6200 (54.7%) 
History of CAD 5155 (30.2%) 
Diabetes 2128 (18.5%) 
Current smoker 4711 (41.7%) 
Dyslipidaemia 5873 (54.9%) 
CAD: coronary heart disease 
Ail hospitals Hospitals without Hospitals with Pvalue 
24 h PCI on site 24 h PCI on site 
6.9% 8.3% 5.8% <Ü.001 
1.9% 2.8% 1.3% <0.001 
1.1 % 0.9% 1.2% 0.104 
0.8% in 2007 (p = 0.04). The percentage of 
patients treated by PCI increased from 4 3 % to at-
tain the high percentage of 85% in 2007. 
Patient management is shown in figure 1. 
Medical treatment without reperfusion was used 
Discussion 
The AMIS Plus registry is a unique ongoing 
multicentre project assessing management of 
acute coronary syndromes in Switzerland. In-hos-
pital mortality and incidence of reinfarction de-
Ma nagement of patients. 
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in 20%, thrombolysis alone in 7%, primary PCI 
in 65% and PCI in addition to thrombolysis (fa-
cilitated PCI) in 8%. Patients admitted to hospi-
tals without PCI facilities were more prone to re-
ceive thrombolysis (2 3 % versus 9%) than those 
admitted to hospitals with PCI facilities . PCI was 
more often used in hospitals with PCI facilities in 
2000 (67% versus 27%) but this difference was 
reduced in 2007 (94% versus 71 %). Mortality and 
reinfarction rate were higher in hospitals without 
catheterisation facilities (table 2), although the 
population was not fully comparable (mean age 
65 ± 11 years versus 63 ± 13 years (p <0.001 ). 
The use of thrombolysis fell from 40.2 % in 
2000 to 2% in 2007. 
Multivariable analysis for in-hospital death 
and MACE are presented in tables 3 and 4. Age 
>65, diabetes, Killip class III-IV, Q wave MI (at 
presentation) and no PCI were the most signifi-
cant predictors of death and MACE. 
Site of hospitalisation (in-house PCI facilities 
or not) is nota predictor of death (OR 1.1, 95 % 
CI 0.9-1.3) or MACE (OR 0.9, 95% CI 0.8-1.1). 
Other variables entered (see the statistics section) 
were not significant predictors. 
The difference in mortality and reinfarction 
is not related to the hospital type but to access to 
PCI. Reperfusion (PCI and thrombolysis) have a 
significant positive impact on survival. 
crease significantly as the number of PCI rises. 
This confirms the benefit of aggressive manage-
ment of STEMI patients. In-hospital mortality 
was 6.9%, which is comparable with other Euro-
pean registries (7% mortality in the Euro Heart 
survey and GRACE [26, 27], 10.4% by MINAP 
[28], 14% for the Danish registry [29]). Classical 
clinical predictors of mortality were as in previous 
trials [30]. As expected, reperfusion (thrombolysis 
and PCI) was associated with a better outcome. 
We confirm the impact of PCI facilities on reper-
fusion strategies. Availability of a catheterisation 
laboratory will of course favour the use of primary 
PCI, with some benefit to the outcome. Our find-
ings are in agreement with other observational 
Figure 2 
Evolution of PCI, mortality and reinfarction from 2000 
to 2007. 
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1 fable 3 
E· Multivariate analysis 
of predictors 
of death. 
fable 4 
Multivariate analysis 
of the composite end 
point predictors of 
major adverse car-
diac events (death, 
reinfarction, stroke). 
OR 95%CI Pvalue 
PCI 0.5 0.4--0.6 <0.001 
Thrombolysis 0.7 0.5-0.9 0.008 
Killip III-IV 8.3 6.7-10.3 <0.001 
Age >65 years 3.6 2.8-4.5 <Ü.001 
Diabetes 1.5 1.2-1.8 <0.001 
LBBB 1.3 1.0-1.7 0.043 
Qwaves 1.3 1.0-1.6 0.030 
>6 h delay 0.8 0.6-1.0 0.022 
OR 95% CI Pvalue 
PCI 0.6 0.5-0.7 <0.001 
Thrombolysis 0.8 0.6-1.0 0.057 
Age >65 years 2.8 2.3-3.3 <0.001 
Killip III-IV 6.9 5.7-8.5 <0.001 
Qwaves 1.5 1.2-1.8 <0.001 
Diabetes 1.5 1.2-1.8 <Ü.001 
LBBB 1.2 1.0-1.6 0.083 
>6 h delay 0.9 0.7-1.0 0.128 
registries [13, 21, 23-25]. In the GRACE registry 
[25] the incidence of in-hospital death was the 
same between patients treated in hospitals with or 
without catheterisation facilities, but this registty 
tested hospital type and not strategy. A different 
conclusion arises from the recent Swedish reg-
istry [31] on long-term outcome of patients with 
STEMI. A significant reduction in short- and 
long-term mortality and reinfarction was found 
when PCI was compared with thrombolysis. We 
show that on-site PCI is not correlated with a bet-
ter outcome, but that PCI itself has a favourable 
impact on mortality and reinfarction. Clearly, ac-
cess to invasive facilities changes the prognosis of 
Swiss patients with STEMI. Efforts have been 
made to improve the proportion of patients trans-
ferred from small to larger hospitals with PCI fa-
cilities for invasive treatment, and over time the 
number of these patients increased. This corre-
lated with a reduction in mortality and reinfarc-
tion. In addition, we noted that 32% of patients 
hospitalised in establishments without PCI did 
not benefit from any t:ype of revascularisation, 
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